These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15114806)

  • 1. Planning and fiscal responsibility will better assist patients with costs.
    Neyhart C
    Nephrol Nurs J; 2004; 31(2):221-2. PubMed ID: 15114806
    [No Abstract]   [Full Text] [Related]  

  • 2. Patients must be free of the worry of paying for medications.
    Smith M
    Nephrol Nurs J; 2004; 31(2):221-2. PubMed ID: 15114805
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of cyclosporine costs on kidney transplants.
    Siegal BR
    Healthspan; 1985; 2(8):15-9. PubMed ID: 10300376
    [No Abstract]   [Full Text] [Related]  

  • 4. An (ongoing) shortsighted view on transplant coverage policy.
    Zumoff R
    Nephrol News Issues; 2012 Mar; 26(3):8, 10. PubMed ID: 22479970
    [No Abstract]   [Full Text] [Related]  

  • 5. What happens when an HMO goes AWOL: patients lose immunosuppressives benefit with little warning.
    Ester D
    Nephrol News Issues; 1996 Jun; 10(6):31. PubMed ID: 8920433
    [No Abstract]   [Full Text] [Related]  

  • 6. Will chronic rejection impact the future of transplantation?
    Kasiske B
    Nephrol News Issues; 1999 Aug; 13(8):45-6. PubMed ID: 10765239
    [No Abstract]   [Full Text] [Related]  

  • 7. The cost of kidney transplantation in Iran.
    Nourbala MH; Einollahi B; Kardavani B; Khoddami-Vishte HR; Assari S; Mahdavi-Mazdeh M; Simforoosh N
    Transplant Proc; 2007 May; 39(4):927-9. PubMed ID: 17524852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing lives through political action as a nursing student.
    Paulson K
    Imprint; 2008; 55(2):40-1. PubMed ID: 18431971
    [No Abstract]   [Full Text] [Related]  

  • 9. Transplant medication resources available after Medicare.
    Jacobs C
    Nephrol News Issues; 1999 Aug; 13(8):11-2, 14. PubMed ID: 10765232
    [No Abstract]   [Full Text] [Related]  

  • 10. Health insurance considerations for adolescent transplant recipients as they transition to adulthood.
    Willoughby LM; Fukami S; Bunnapradist S; Gavard JA; Lentine KL; Hardinger KL; Burroughs TE; Takemoto SK; Schnitzler MA
    Pediatr Transplant; 2007 Mar; 11(2):127-31. PubMed ID: 17300489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insurance woes threaten gift of life.
    Harris P
    Nephrol News Issues; 2008 Aug; 22(9):48-9. PubMed ID: 18778007
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacoeconomics of immunosuppressive agents in renal transplant recipients.
    Bennett WM; Olyaei AJ
    Transplant Proc; 1999 May; 31(3A Suppl):6S. PubMed ID: 10330949
    [No Abstract]   [Full Text] [Related]  

  • 13. Retrospective study on the utilization and cost of immunosuppressive agents among kidney transplant recipients in Taiwan: a 5-year review.
    Lee EK; Tseng PL
    Transplant Proc; 2008 Sep; 40(7):2214-7. PubMed ID: 18790196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of renal transplant in Belgium.
    Chaib-Eddour D; Chaib-Eddour H; Malaise J; Mourad M; Squifflet JP
    Transplant Proc; 2005; 37(6):2819-20. PubMed ID: 16182818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What are the incentives for the ESRD patient?
    Coutts LR
    Nephrol News Issues; 1992 Jul; 6(7):5, 12. PubMed ID: 1407060
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
    Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
    Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient questions about transplantation: a resource guide.
    Neyhart CD
    Nephrol Nurs J; 2009; 36(3):279-85. PubMed ID: 19588695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a new combined immunosuppressive and anti-infectious regimen in kidney transplantation.
    Wasserfallen JB; Kast-Brückner M; Manuel O; Venetz JP; Meylan PR; Pascual M
    Int J Technol Assess Health Care; 2008; 24(3):312-7. PubMed ID: 18601799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey.
    Shrank WH; Young HN; Ettner SL; Glassman P; Asch SM; Kravitz RL
    Am J Manag Care; 2005 Jan; 11(1):16-22. PubMed ID: 15697096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunosuppressive treatment following kidney transplantation].
    Griebsch I
    Pharm Unserer Zeit; 2005; 34(4):322-30. PubMed ID: 16041960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.